We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current SAGE market cap is 474.63M. The company's latest EPS is USD -6.5169 and P/E is -1.18.
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 77.97M | 7.9M | 8.65M | 11.87M | 12.82M |
| Operating Income | -42.07M | -117.68M | -111.3M | -101.2M | -102.19M |
| Net Income | -32.71M | -108.48M | -102.85M | -93.55M | -95.78M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 1.11B | 6.31M | 7.69M | 86.46M | 41.24M |
| Operating Income | 596.23M | -460.91M | -546.99M | -579.85M | -432.37M |
| Net Income | 606.07M | -457.89M | -532.78M | -541.49M | -400.67M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 882.28M | 767.6M | 697.11M | 622.43M | 547.22M |
| Total Liabilities | 82.75M | 61.8M | 69.04M | 70.6M | 82.13M |
| Total Equity | 799.53M | 705.8M | 628.06M | 551.84M | 465.09M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 2.16B | 1.83B | 1.36B | 882.28M | 547.22M |
| Total Liabilities | 86.91M | 96.26M | 103.85M | 82.75M | 82.13M |
| Total Equity | 2.07B | 1.73B | 1.25B | 799.53M | 465.09M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -540.59M | -37.83M | -118.27M | -200.63M | -267.19M |
| Investing | 442.91M | 139.44M | 139.05M | 220.1M | 266.68M |
| Financing | 6.03M | 1.56M | 9.63M | 10.67M | 10.66M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 664.28M | -378.18M | -460.04M | -540.59M | -267.19M |
| Investing | 442.68M | -1B | 325.43M | 442.91M | 266.68M |
| Financing | 426.76M | 13.33M | 3.07M | 6.03M | 10.66M |
| Market Cap | 474.63M |
| Price to Earnings Ratio | -1.18 |
| Price to Sales Ratio | 11.51 |
| Price to Cash Ratio | 5.86 |
| Price to Book Ratio | 1.02 |
| Dividend Yield | - |
| Shares Outstanding | 61.48M |
| Average Volume (1 week) | 1.41M |
| Average Volume (1 Month) | 1.5M |
| 52 Week Change | -62.14% |
| 52 Week High | 20.73 |
| 52 Week Low | 4.62 |
| Spread (Intraday) | 0.84 (10.58%) |
| Company Name | Sage Therapeutics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.sagerx.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
